risks and side effects of bpc-157 and tb-500 BPC-157: Miracle Healing Peptide or Hidden Danger? The Hidden Risks of BPC‑157:

Safety and Clinical Supervision Though the BPC-157 peptide is not FDA-approved for general medical use, there is ample evidence showcasing its effectiveness

This practice introduces cross-contamination and stability risks

Early evidence for the potential efficacy of this route was published in 1999, where 18 patients with B12 deficiency treated exclusively with 712 days of 2 mg of sublingual cobalamin daily had 4 times higher B12 levels compared to pre-treatment, reaching therapeutic ranges ( There have also been further studies comparing treatment outcomes from the sublingual route to the more established IM and oral routes

If these occur, discontinue tirzepatide immediately and seek medical evaluation

Always consult a healthcare professional for health concerns